ClinicalTrials.gg
CompletedNCT03474198TRUNCATE-TBUpdated Aug 14, 2023

Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis

A Phase 2/3 interventional study of Rifampicin and Isoniazid in Tuberculosis, Pulmonary, sponsored by University College, London. Completed at 18 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-08-14.

Sponsored by University College, London · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
675
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 15 studies testing linezolid in Tuberculosis, Pulmonary — 4 open to participants now, 6 under way, 4 of them phase 3. Linezolid · Tuberculosis, Pulmonary.

Enrollment
3rd of 15
675 · median 309
Started
2018
the only one that year
Phase 2/3
3 of 15
1 open now
Registered
5th of 15
by date
Lead sponsor
2 of 15
University College, London

Among the 15 studies testing linezolid in Tuberculosis, Pulmonary, this one is the 3rd largest by enrollment, is the only one that started in 2018, is one of 3 in phase 2/3, and was the 5th registered.

Tuberculosis, Pulmonary

320 studies on the registry are indexed under Tuberculosis, Pulmonary; 72 are open to participants now.

Browse Tuberculosis, Pulmonary studies →

Open to participants now

4 of the 15 studies testing linezolid in Tuberculosis, Pulmonary are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About linezolid

Linezolid: first FDA approval 2000 (ZYVOX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 47 Tuberculosis, Pulmonary studies recruiting now, 22 (47%) set no upper age limit and 21 (45%) stop at 75 or younger; 12 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing linezolid in Tuberculosis, Pulmonary, or all of them as a file.
02

Study summary

The current standard management strategy for drug-sensitive pulmonary tuberculosis (TB) is to treat with multiple drugs for 6 months, although patients often fail to adhere to the long treatment, leading to poor clinical outcomes including drug resistance, which is expensive and difficult to treat.

The TRUNCATE-TB trial evaluates an alternative strategy (the TRUNCATE-TB Management Strategy) comprising treatment for 2 months (8 weeks, extended to 12 weeks if inadequate clinical response) with a regimen predicted to have enhanced sterilising activity ("boosted regimen") and monitoring closely after treatment cessation. Those who relapse (predicted to be always drug sensitive and likely to occur early) will be retreated with a standard 6 month regimen.

The trial is a randomized, open-label, multi-arm, multi-stage (MAMS) trial to test the hypothesis that the TRUNCATE-TB Management Strategy is non-inferior to the standard management strategy in terms of longer-term outcomes (clinical status at 96 weeks). If non-inferiority is demonstrated then the advantages/disadvantages of implementing the strategy will be explored in secondary outcomes (from patient and programme perspective).

The trial will evaluate the TRUNCATE-TB Management Strategy with 4 potential boosted regimens (180 per arm, total 900 with the standard TB management strategy arm). The boosted regimens include new drugs (licensed drugs, repurposed from other indications) and optimized doses of standard drugs, selected based on consideration of maximal sterilising effect, absence of drug-drug interactions, as well as safety and tolerability over a period of 2 months

03

Conditions studied

  • Tuberculosis, Pulmonary
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 65 years
  2. Clinical symptoms consistent with pulmonary TB and/or evidence of pulmonary TB on chest X-ray (CXR)
  3. Sputum GeneXpert test positive
  4. Willing to comply with the study visits and procedures
  5. Resident at a fixed address
  6. Willing to have directly observed therapy
  7. Willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  1. Taken more than 10 daily doses of standard anti-TB medication or fluoroquinolones during the 3 months prior to randomisation
  2. Previous active TB disease for which treatment was given prior to the current episode
  3. Known or suspected extra-pulmonary TB
  4. Severe clinical pulmonary TB
  5. Sputum smear 3+ on microscopy*
  6. Cavity size > 4cm on screening CXR*
  7. Presence of rifampicin resistance on GeneXpert test
  8. Poorly-controlled diabetes that, in the opinion of the investigator, is unlikely to be controlled with available management strategies
  9. Active requiring systemic chemotherapy or radiotherapy
  10. Known surface antigen positive and/or antibody positive, unless liver function tests consistently within normal range for at least 2 years
  11. History of myocardial infarction, congestive cardiac failure, cardiac arrhythmias or any known congenital cardiac problems
  12. History of severe chronic lung disease with symptom score of ≥3 on MRC breathlessness scale
  13. History of seizures
  14. Current tendinitis or history of tendinopathy associated with fluoroquinolone use
  15. Symptomatic peripheral neuropathy causing greater than minimal interference with usual social and functional activities
  16. Current alcohol or drug abuse
  17. Women who are currently pregnant or breast-feeding
  18. Women of unwilling or unable to use appropriate effective for the first 6 months of the trial
  19. Known allergy to one or more of the study drugs
  20. Taking a concomitant medication that has a known or predicted interaction with any of the study drugs to which the patient might be randomised, or is known to prolong the
  21. Taking any drugs or use of systemic for more than 2 weeks prior to screening
  22. Colour blindness detected by Ishihara test

23.12-lead at screening shows QTc greater than 450ms and/or any other clinically-significant abnormality such as arrhythmia or ischaemia

24.Any of the following laboratory parameters at screening:

  • Absolute neutrophil \<1000 cells/mL, \<7.0 g/dL, OR count \<50,000 cells/mm3
  • of \<60ml/min (calculated using Cockcroft-Gault equation)
  • greater than 3 times the
  • Uncorrected serum potassium \<3.5 mmol/L

    25. antibody positive at screening*

    26.Any other significant condition (e.g. psychiatric illness, chronic diarrhoeal disease), that would, in the opinion of the investigator, compromise the patient's safety or outcome in the trial or lead to poor compliance with study visits and protocol requirements

    27.Participation in other clinical intervention trial or research protocol

Note: *Criteria may be modified in later stages of the trial

-

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
675 participants (actual)

Study arms

  • Active comparator
    Standard TB Management Strategy

    Standard combination treatment for pulmonary TB of 8 weeks rifampicin, isoniazid, pyrazinamide, ethambutol, then 16 weeks rifampicin, isoniazid only

    Drug: Rifampicin · Drug: Isoniazid · Drug: Pyrazinamide · Drug: Ethambutol

  • Experimental
    TRUNCATE-TB Management Strategy using Regimen B

    TRUNCATE-TB Management Strategy: 8 weeks\* of initial treatment using Regimen B; close monitoring after treatment completion; treatment of relapse with 24 weeks of standard treatment. \*If persistent symptoms and positive smear at week 8, extend to 12 weeks of treatment using Regimen B; if persistent symptoms and positive smear at week 12, switch to standard treatment regimen and extend to 24 weeks of treatment. Regimen B: Rifampicin (35mg/kg), isoniazid, pyrazinamide, ethambutol, linezolid

    Drug: Isoniazid · Drug: Pyrazinamide · Drug: Ethambutol · Drug: Linezolid · Drug: Rifampicin

  • Experimental
    TRUNCATE-TB Management Strategy using Regimen C

    TRUNCATE-TB Management Strategy as described above, using Regimen C in place of B. Regimen C: Rifampicin (35mg/kg), isoniazid, pyrazinamide, ethambutol, clofazimine

    Drug: Isoniazid · Drug: Pyrazinamide · Drug: Ethambutol · Drug: Clofazimine · Drug: Rifampicin

  • Experimental
    TRUNCATE-TB Management Strategy using Regimen D

    TRUNCATE-TB Management Strategy as described above, using Regimen D in place of B. Regimen D: Rifapentine, isoniazid, pyrazinamide, linezolid, levofloxacin

    Drug: Isoniazid · Drug: Pyrazinamide · Drug: Linezolid · Drug: Rifapentine · Drug: Levofloxacin

  • Experimental
    TRUNCATE-TB Management Strategy using Regimen E

    TRUNCATE-TB Management Strategy as described above, using Regimen E in place of B. Regimen E: Isoniazid, pyrazinamide, ethambutol, linezolid, bedaquiline

    Drug: Isoniazid · Drug: Pyrazinamide · Drug: Ethambutol · Drug: Linezolid · Drug: Bedaquiline

Interventions

06

What researchers measure

Primary outcomes

  1. Unsatisfactory clinical outcome at week 96 after randomisation

    As defined by ongoing requirement for TB treatment at week 96 OR ongoing TB disease activity at week 96 (clinical, microbiological and/or imaging evidence) OR death before week 96

    Time frame: 96 weeks

Secondary outcomes

  1. Acceptability of the strategy using trial-specific questionnaire

    7-item trial-specific questionnaire

    Time frame: 96 weeks

  2. Total days on TB drug treatment

    Time frame: 96 weeks

  3. Time off work or study due to illness/treatment

    Time frame: 96 weeks

  4. Total Quality of life using MOS-HIV questionnaire

    MOS-HIV questionnaire

    Time frame: 96 weeks

  5. Respiratory disability at week 96

    Time frame: 96 weeks

  6. Total Grade 3 or 4 clinical adverse events

    Time frame: 96 weeks

  7. Total serious adverse events

    Time frame: 96 weeks

  8. Death

    Time frame: 96 weeks

  9. Adherence to TB medication

    Time frame: Either during first 8 weeks or at any time during period when TB treatment is prescribed

  10. Treatment default

    Time frame: Either during first 8 weeks or at any time during period when TB treatment is prescribed

  11. Acquired drug resistance by week 96

    Time frame: 96 weeks

  12. Community transmission risk

    Time frame: 96 weeks

07

Study locations

18 sites
  • National Institute of TB and Respiratory Diseases
    New Delhi, India
  • Universitas Padjadjaran
    Bandung, Indonesia
  • Persahbahatan Hospital
    Jakarta, Indonesia
  • Wahidin Sudirohusodo Hospital
    Makassar, Indonesia
  • Saiful Anwar Hospital
    Malang, Indonesia
  • Soetomo General Hospital
    Surabaya, Indonesia
  • Perpetual Succour Hospital
    Cebu, Philippines
  • De La Salle Health Sciences Institute
    Manila, Philippines
  • Lung Center Philippines
    Manila, Philippines
  • Philippines Tuberculosis Society Incorporated (PTSI)
    Manila, Philippines
  • Tropical Disease Foundation
    Manila, Philippines
  • Quezon Institute
    Quezon City, Philippines
  • National University Hospital
    Singapore, Singapore
  • King Chulalongkorn Memorial Hospital
    Bangkok, Thailand
  • Central Chest Institute of Thailand
    Nonthaburi, Thailand
  • Infectious Diseases Institute
    Kampala, Uganda
  • Joint Clinical Research Centre
    Kampala, Uganda
  • Joint Clinical Research Centre
    Mbarara, Uganda
08

References and documents

Publications

  • Converse PJ, Almeida DV, Tasneen R, Saini V, Tyagi S, Ammerman NC, Li SY, Anders NM, Rudek MA, Grosset JH, Nuermberger EL. Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer. PLoS Negl Trop Dis. 2018 Aug 13;12(8):e0006728. doi: 10.1371/journal.pntd.0006728. eCollection 2018 Aug. PubMed 30102705 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Jan 2022, 45 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2018
First posted
Mar 22, 2018
StartActual
Mar 21, 2018
Primary completionActual
Jan 20, 2022
CompletionActual
Jan 20, 2022
Last update
Aug 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03474198
Collaborators
National University Hospital, Singapore, Singapore Clinical Research Institute (SCRI)
Responsible party
Sponsor
First posted
Mar 22, 2018
Start date
Mar 21, 2018
Primary completion
Jan 20, 2022
Completion
Jan 20, 2022
Last update
Aug 14, 2023

Study contacts

Nicholas Paton
study director · National University Hospital, Singapore

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ethambutol · Linezolid · Clofazimine · Rifapentine · Levofloxacin · Bedaquiline

Start the discussion